Clinical trials for Hemophilia A
19 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPhase 4NCT05936580Nuwiq Dosing and Outcomes In the ManagEment of Women/Girls With Haemophilia A Needing FVIII Treatment for SurgeryOctapharma · PI: Johannes Oldenburg
- ACTIVE NOT RECRUITINGNCT07161687A Study to Learn About the Study Medicine -Hympavzi in Congenital Hemophilia Patients Without Inhibitors in Japan.Pfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPhase 4NCT06864975Assessing Different FVIII Doses and Frequencies in Immune Tolerance Induction (ITI) with ADVATE Among Hemophilia a Boys with Inhibitor (INITIATE Study)Runhui WU
- RECRUITINGPhase 1NCT06579144Pharmacokinetic Comparison of Efanesoctocog Alfa vs Other EHL-rFVIII Products in Participants With Severe Haemophilia ASwedish Orphan Biovitrum · PI: Elena Santagostino, MD
- RECRUITINGPhase 3NCT06738485Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII ProductsCSL Behring · PI: Study Director
- RECRUITINGNCT06684314A Study to Evaluate Impact of Efanesoctocog Alfa on Long-term Joint Health in Participants With Hemophilia A in TaiwanSanofi
- RECRUITINGNCT07414511Hemophilia A Research ProgramUniversity of Washington · PI: Jill M Johnsen, MD
- RECRUITINGEarly Phase 1NCT06345833Topical and Local TXA in Facelifts - A Randomized Controlled Double Blinded StudyUniversity of Minnesota · PI: Jenna Van Beck, MD
- RECRUITINGNCT06352216Prevalence of Synovitis in Patients With Haemophilia AUniversity Hospital, Bonn · PI: Andreas C Strauss, PD Dr. med.
- ACTIVE NOT RECRUITINGPhase 3NCT05817812A Study Evaluating Physical Activity and Joint Health in Severe Haemophilia A Patients ≥12 Years Treated Once Weekly With Efanesoctocog AlfaSwedish Orphan Biovitrum · PI: Study Physician, MD, PhD
- RECRUITINGN/ANCT05629130Embolization in Hereditary CoagulopathiesUniversity of Sao Paulo General Hospital · PI: Fabiane E FArias, PT
- RECRUITINGPhase 3NCT05611801A Clinical Trial of Study Medicine (Marstacimab) in Pediatric Patients With Hemophilia A or Hemophilia BPfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGPhase 4NCT06320626Pharmacokinetic-guided Dosing of EmicizumabKathelijn Fischer · PI: Study Officials Fischer, Dr, MD
- RECRUITINGPhase 4NCT04567511Hemlibra in Mild Hemophilia AIndiana Hemophilia &Thrombosis Center, Inc. · PI: Amy D Shapiro, MD
- RECRUITINGEarly Phase 1NCT05454774A Study of FVIII Gene Therapy for Hemophilia AInstitute of Hematology & Blood Diseases Hospital, China · PI: Lei Zhang, MD
- ACTIVE NOT RECRUITINGPhase 3NCT04370054Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A AdultsPfizer · PI: Pfizer CT.gov Call Center
- RECRUITINGNCT04023019Treatment of Hemophilia A Patients With FVIII InhibitorsEmory University · PI: Robert Sidonio, MD, MSc
- RECRUITINGNCT04131036Effects of Emicizumab vs. Factor VIII Prophylaxis on Joint and Bone Health in Severe Hemophilia AWashington Institute for Coagulation · PI: Rebecca Kruse-Jarres, MD, MPH
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03588299Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle"Bayer